Trial Profile
A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Ulocuplumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jun 2022 This trial has been completed in Romania, according to European Clinical Trials Database record.
- 10 Jun 2022 Planned number of patients changed from 126 to 157.
- 24 Jan 2020 Status changed from completed to discontinued.